Comparison of four different regimens against Helicobacter pylori as a first-line treatment: A prospective, cross-sectional, comparative, open trial in Chinese children

Helicobacter Pylori

Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: a Network Meta-Analysis

Gastroenterology

Rokkas T, Gisbert JP, Malfertheiner P, Niv Y, Gasbarrini A, Leja M, Megraud F, O'Morain C, Graham DY

doi: 10.1053/j.gastro.2021.04.012

Helicobacter Pylori

Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H pylori management (Hp-EuReg)

Helicobacter.

Nyssen OP, Pérez-Aisa Á, Tepes B, Rodrigo-Sáez L, Romero PM, Lucendo A, Castro-Fernández M, Phull P, Barrio J, Bujanda L, Ortuño J, Areia M, Brglez Jurecic N, Huguet JM, Alcaide N, Voynovan I, María Botargues Bote J, Modolell I, Pérez Lasala J, Ariño I, Jonaitis L, Dominguez-Cajal M, Buzas G, Lerang F, Perona M, Bordin D, Axon T, Gasbarrini A, Marcos Pinto R, Niv Y, Kupcinskas L, Tonkic A, Leja M, Rokkas T, Boyanova L, Shvets O, Venerito M, Bytzer P, Goldis A, Simsek I, Lamy V, Przytulski K, Kunovský L, Capelle L, Milosavljevic T, Caldas M, Garre A, Mégraud F, O'Morain C, Gisbert JP, Hp-EuReg Investigators

doi: 10.1111/hel.12686.

Helicobacter Pylori

Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan

Gut.

Suzuki S, Gotoda T, Kusano C, Ikehara H, Ichijima R, Ohyauchi M, Ito H, Kawamura M, Ogata Y, Ohtaka M, Nakahara M, Kawabe K

doi: 10.1136/gutjnl-2019-319954.

Celiac DiseaseHelicobacter Pylori

Helicobacter pylori infection in children with celiac disease: Multi-center, cross-sectional study

Helicobacter.

Bayrak NA, Tutar E, Volkan B, Sahin Akkelle B, Polat E, Kutluk G, Ertem D

doi: 10.1111/hel.12691.

Helicobacter Pylori

Efficacy of bismuth added to standard triple therapy as the first-line eradication regimen for Helicobacter pylori infection

Helicobacter

Kim YJ, Chung WC, Kim DB

doi: 10.1111/hel.12792

Helicobacter Pylori

Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial

Lancet Infect Dis.

Liou JM, Chen CC, Chang CM, Fang YJ, Bair MJ, Chen PY, Chang CY, Hsu YC, Chen MJ, Chen CC, Lee JY, Yang TH, Luo JC, Chen CY, Hsu WF, Chen YN, Wu JY, Lin JT, Lu TP, Chuang EY, El-Omar EM, Wu MS, Taiwan Gastrointestinal Disease and Helicobacter Consortium.

doi: 10.1016/S1473-3099(19)30272-5.

Helicobacter Pylori

Pylera® plus ranitidine vs Pylera® plus esomeprazole in first-line treatment of Helicobacter pylori infection: Two pilot studies

Helicobacter.

Ciccaglione AF, Cellini L, Marzio L

doi: 10.1111/hel.12606.

Helicobacter Pylori

PPI-amoxicillin dual therapy four times daily is superior to guidelines recommended regimens in the Helicobacter pylori eradication therapy within Asia: A systematic review and meta-analysis

Helicobacter

Li C, Shi Y, Suo B, Tian X, Zhou L, Song Z

doi: 10.1111/hel.12816

Further Publications

Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial

Lancet Gastroenterol Hepatol

Vogel A, Qin S, Kudo M, Su Y, Hudgens S, Yamashita T, Yoon JH, Fartoux L, Simon K, López C, Sung M, Mody K, Ohtsuka T, Tamai T, Bennett L, Meier G, Breder V

doi: 10.1016/S2468-1253(21)00110-2

Related content

Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: a Network Meta-Analysis

Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H pylori management (Hp-EuReg)

Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan

Helicobacter pylori infection in children with celiac disease: Multi-center, cross-sectional study

Efficacy of bismuth added to standard triple therapy as the first-line eradication regimen for Helicobacter pylori infection

Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial

Pylera® plus ranitidine vs Pylera® plus esomeprazole in first-line treatment of Helicobacter pylori infection: Two pilot studies

PPI-amoxicillin dual therapy four times daily is superior to guidelines recommended regimens in the Helicobacter pylori eradication therapy within Asia: A systematic review and meta-analysis

Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial